Elevated Natalizumab Levels in MS May Not Be Linked With PML Risk Elevated Natalizumab Levels in MS May Not Be Linked With PML Risk

In multiple sclerosis (MS) patients treated with natalizumab, the risk of developing progressive multifocal leukoencephalopathy (PML) does not appear to be associated with high blood levels of the drug, preliminary research from the Netherlands suggests.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news